Literature DB >> 12387582

Diurnal rhythm and effects of oral contraceptives on serum dehydroepiandrosterone sulfate (DHEAS) are related to alterations in serum albumin rather than to changes in adrenocortical steroid secretion.

K Carlström1, R Karlsson, B Von Schoultz.   

Abstract

Dehydroepiandrosterone sulfate (DHEAS), which is of almost exclusive adrenal origin, is important for the androgen status in women and prepubertal children, and DHEAS assays are used in the investigation of hyperandrogenism. There are conflicting reports concerning a diurnal variation in serum DHEAS. Although of adrenocortical origin, serum DHEAS levels are decreased by oral contraceptives (OCs). DHEAS is strongly bound to serum albumin and has a very low metabolic clearance rate. The present study was performed in order to investigate whether a diurnal variation in serum DHEAS exists and, if so, whether this diurnal variation and the decreased DHEAS levels following OC use are related to alterations in adrenocortical steroids or to changes in serum albumin. Serum concentrations of DHEAS, dehydroepiandrosterone (DHEA), cortisol and albumin were determined in blood samples taken every half hour over a 24-h period in 10 healthy women before and during use of combined OCs. Significant and frequently synchronous diurnal variations in serum DHEAS and albumin were found before as well as during OC use. These variations were not synchronous with the diurnal variation in DHEA. OCs significantly decreased serum DHEAS and albumin levels. A multiple regression analysis showed changes in albumin to be the most decisive factor for the diurnal variation as and for OC-induced changes in DHEAS. Changes in serum DHEAS during the day and following OC use are related to alterations in its main binding protein, serum albumin, rather than to changes in adrenocortical steroid secretion.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12387582     DOI: 10.1080/00365510260296519

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest        ISSN: 0036-5513            Impact factor:   1.713


  15 in total

1.  Optimizing bone health in anorexia nervosa and hypothalamic amenorrhea: new trials and tribulations.

Authors:  Joo-Pin Foo; Ole-Petter R Hamnvik; Christos S Mantzoros
Journal:  Metabolism       Date:  2012-01-31       Impact factor: 8.694

2.  Modulation of higher-primate adrenal androgen secretion with estrogen-alone or estrogen-plus-progesterone intervention.

Authors:  Alan J Conley; Frank Z Stanczyk; John H Morrison; Pawel Borowicz; Kurt Benirschke; Nancy A Gee; Bill L Lasley
Journal:  Menopause       Date:  2013-03       Impact factor: 2.953

3.  Genetic and environmental effects on diurnal dehydroepiandrosterone sulfate concentrations in middle-aged men.

Authors:  Elizabeth C Prom-Wormley; Timothy P York; Kristen C Jacobson; Lindon J Eaves; Sally P Mendoza; Dirk Hellhammer; Nicole Maninger; Seymour Levine; Sonia Lupien; Michael J Lyons; Richard Hauger; Hong Xian; Carol E Franz; William S Kremen
Journal:  Psychoneuroendocrinology       Date:  2011-05-12       Impact factor: 4.905

4.  Effect of the ethinylestradiol/levonorgestrel combined oral contraceptive on the activity of cytochrome P4503A in obese women.

Authors:  Alison Edelman; Myrna Munar; Miriam R Elman; Dennis Koop; Ganesh Cherala
Journal:  Br J Clin Pharmacol       Date:  2012-09       Impact factor: 4.335

5.  Higher DHEA-S (dehydroepiandrosterone sulfate) levels are associated with depressive symptoms during the menopausal transition: results from the PENN Ovarian Aging Study.

Authors:  Mary Frances Morrison; Ellen W Freeman; Hui Lin; Mary D Sammel
Journal:  Arch Womens Ment Health       Date:  2011-07-20       Impact factor: 3.633

Review 6.  Mutual Shaping of Circadian Body-Wide Synchronization by the Suprachiasmatic Nucleus and Circulating Steroids.

Authors:  Yifan Yao; Rae Silver
Journal:  Front Behav Neurosci       Date:  2022-06-01       Impact factor: 3.617

7.  Tamoxifen and megestrol acetate for postmenopausal breast cancer: diverging effects on liver proteins, androgens, and glucocorticoids.

Authors:  L Löfgren; B Wallberg; N Wilking; T Fornander; L E Rutqvist; K Carlström; B von Schoultz; E von Schoultz
Journal:  Med Oncol       Date:  2004       Impact factor: 3.064

8.  Androgens in women with anorexia nervosa and normal-weight women with hypothalamic amenorrhea.

Authors:  K K Miller; E A Lawson; V Mathur; T L Wexler; E Meenaghan; M Misra; D B Herzog; A Klibanski
Journal:  J Clin Endocrinol Metab       Date:  2007-02-06       Impact factor: 5.958

9.  Adrenal glucocorticoid and androgen precursor dissociation in anorexia nervosa.

Authors:  E A Lawson; M Misra; E Meenaghan; L Rosenblum; D A Donoho; D Herzog; A Klibanski; K K Miller
Journal:  J Clin Endocrinol Metab       Date:  2009-01-21       Impact factor: 5.958

10.  Use of ethinylestradiol/drospirenone combination in patients with the polycystic ovary syndrome.

Authors:  Ruchi Mathur; Olga Levin; Ricardo Azziz
Journal:  Ther Clin Risk Manag       Date:  2008-04       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.